LIXT News and Press, Lixte Biotechnology Holdings Inc. From 12/01/20

East Setauket, NY, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) (Nasdaq: Common stock – LIXT; Warrants – LIXTW), a drug discovery company that uses biomarker technology to identify enzyme target...

WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the closing of the follow-on offering for its client Lixte Biotechnology Holdings, Inc. 1,200,000 units consisting of one share of common stock and one warrant were sold for a total of $...

Lixte Biotechnology (LIXT) common stock and warrants to begin trading on the Nasdaq Capital Market on November 25, 2020, under the symbols "LIXT" and "LIXTW”.Company announced the pricing of its underwritten public offering of 1.2M units of securities at $4.75 per unit. Each unit ...

East Setauket, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT)(“Lixte” or the “Company”), today announced the pricing of its underwritten public offering of 1,200,000 units of securities at an offering price of $4.75 per un...

Lixte Biotechnology Holdings (LIXT) to raise $9M by offering 1.5M shares at a price range of $5.75-$6.75. Underwriters' over-allotment is an additional 225K shares.At an assumed price of $6.25/share, net proceeds to be ~$8.14M (or ~$9.41M if the underwriters exercise their option in...

Quick Take Lixte Biotechnology Holdings ( LIXT ) has filed to raise $10 million in an IPO of its common stock, according to an S-1 registration statement . The firm is developing a pipeline of treatments for various types of cancers and vascular and metabolic diseases. LIXT is outsourci...

While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management's SPAC CM Life Sciences (CMLF) upsized to raise $385 million. Led by the firms' founders, Eli Casdin and Keith Meister, the company plans to target the life ...

EAST SETAUKET, NY, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) announced an agreement with the Foundation for Angelman Syndrome Therapeutics (FAST) to collaborate in supporting preclinical studies of the potential benefit of Lixte’s proprietar...

EAST SETAUKET, NY, July 21, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) today announced the appointment of Dr. James Miser as its Chief Medical Officer commencing August 1, 2020. Dr. John S. Kovach, founder and CEO of Lixte, commented, “We are thr...

EAST SETAUKET, NY, April 30, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) noted that investigators at the National Cancer Institute (NCI) and National Institute of Neurological Disorders and Stroke (NINDS) reported that Lixte’s lead clinical compound,...